1 active not recruiting, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Flare Therapeutics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Patients With Metastatic Castration-Resistant Prostate Cancer FX-111 - Metastatic Castration Resistant Prostate Cancer, mCRPC | Phase 1 | Recruiting | Flare Therapeutics Inc. | 60 | 2026-07-01 | 2026-09-24 |
| A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab) - Advanced Urothelial Carcinoma, Oral Drug Administration | Phase 1 | Active not recruiting | Flare Therapeutics Inc. | 120 | 2023-08-24 | 2026-08-12 |
Prostatic Neoplasms (1) · Prostatic Neoplasms, Castration-Resistant (1)
pembrolizumab (1)
United States (2)
Gopa Iyer, MD (1)